TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30587066

Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Supervised resistance training
Number of subjects: 156

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 156
Study: 28666682

Group type: EXPERIMENTAL
Intervention: Family-led rehabilitation training (structured training including information provision, joint goal setting, carer training, and task-specific training) for up to 2 months initiated in hospital and continued at home.
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Family-led rehabilitation training (intervention group).
Number of subjects: 1250
Study: 26307620

Group type: EXPERIMENTAL
Intervention: School-based smoke-free intervention (SFI) consisting of six interactive educational activities.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group receiving usual education.
Number of subjects: 360
Study: 22476244

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Glucosamine sulfate (1,500 mg/day) plus exercise therapy
Number of subjects: 37
Study: 22189721

Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 199

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 199
Study: 19502478

Group type: EXPERIMENTAL
Intervention: Parent Skills with Behavioral Couples Therapy (PSBCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Individual‐Based Treatment (IBT)
Number of subjects: 30
Study: 16861432

Group type: EXPERIMENTAL
Intervention: Positive intravascular fluid balance of 0-1000 mL (Group 1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Positive intravascular fluid balance of 1000-2000 mL (Group 2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Positive fluid balance
Number of subjects: 32

Group type: COMPARATOR
Intervention: Restricted intravascular fluid balance
Number of subjects: 32
Study: 12942587

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 500 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17069099

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10588144

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) active for the first 4 weeks, then withheld for the next 4 weeks.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group with SCS switched off for 4 weeks before the end of the study.
Number of subjects: 24
Study: 8767376

Group type: EXPERIMENTAL
Intervention: Mechanical lavage with 2 l of polyethylene glycol (PEG) solution combined with a laxative (group A, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lavage with 4 l of PEG alone (group B, n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conventional surgery
Number of subjects: 100
Study: 1672547

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 6752563

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dimethpyrindene (Fenistil) and 5 mg/kg cimetidine (Tagamet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dimethpyrindene and 10 mg/kg cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H1- + H2-receptor antagonists
Number of subjects: 0
Study: 31800611

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (30 mg) before surgery
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo before surgery
Number of subjects: 203
Study: 28286194

Group type: EXPERIMENTAL
Intervention: Rectal tacrolimus (0.5 mg/mL)
Number of subjects: 21
Study: 26025215

Group type: EXPERIMENTAL
Intervention: SALdável Program intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 24097340

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5 %
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.5 %
Number of subjects: 60
Study: 23031464

Group type: EXPERIMENTAL
Intervention: E2 (125 mg PFA/kg BD)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: E3 (250 mg PFA/kg BD)
Number of subjects: 525

Group type: COMPARATOR
Intervention: C (BD based on maize‐soybean meal with no other additions)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: PFA inclusion level
Number of subjects: 525
Study: 19534614

Group type: EXPERIMENTAL
Intervention: Indigowood root (IR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 20
Study: 17428602

Group type: EXPERIMENTAL
Intervention: Panoramic visor respirator
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bi-ocular respirator
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (unprotected)
Number of subjects: 14
Study: 15321802

Group type: EXPERIMENTAL
Intervention: Consumption of > or =2 servings of fish per week
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Consumption of > or =1 serving of tuna or dark fish per week
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Higher fish consumption
Number of subjects: 229
Study: 11448249

Group type: EXPERIMENTAL
Intervention: Clonidine (4, 6, and 8 mcg/kg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9514534

Group type: EXPERIMENTAL
Intervention: Pringle's maneuver
Number of subjects: 20
Study: 7985256

Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg b.i.d.
Number of subjects: 48
Study: 30479242

Group type: EXPERIMENTAL
Intervention: Collaborative shared care (CSC) program between traditional and faith healers (T&FHs) and biomedical providers for the treatment of psychotic disorders
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Training workshops for early and mid-career researchers
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mentoring for early career researchers
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Research capacity building
Number of subjects: 35
Study: 28189771

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg (2 puffs of 2.5 μg)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg (2 puffs of 1.25 μg)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 401
Study: 25915834

Group type: EXPERIMENTAL
Intervention: Topical EBI-005 (5 mg/mL)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 159
Study: 23635736

Group type: EXPERIMENTAL
Intervention: Immediate surgery (n=64)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Individually tailored therapy (n=62)
Number of subjects: 578
Study: 22011408

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional CSII
Number of subjects: 12
Study: 18385391

Group type: EXPERIMENTAL
Intervention: Niacinamide (500 to 1500 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Niacinamide (500 to 1500 mg/d) among compliant patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 16437738

Group type: EXPERIMENTAL
Intervention: Indirect moxibustion on acupuncture points ST‐36 and SP‐6 for 20 minutes per day for 1 week
Number of subjects: 24
Study: 12915954

Group type: EXPERIMENTAL
Intervention: Menthol (100 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10691755

Group type: EXPERIMENTAL
Intervention: Community programme (media advocacy, youth anti-tobacco activities, family communications about tobacco use, reduction of youth access to tobacco)
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Community programme
Number of subjects: 1700

Group type: COMPARATOR
Intervention: School based prevention programme
Number of subjects: 1700
Study: 9137841

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divalproex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake blockers
Number of subjects: 0
Study: 8212819

Group type: EXPERIMENTAL
Intervention: Two doses of B-WC vaccine at 7, 14, or 28-42 day intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of B-WC vaccine at 3-day intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different time intervals tested (3-42 days) for vibriocidal antibody responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B-WC vaccine with sodium bicarbonate powder
Number of subjects: 0
Study: 3940333

Group type: EXPERIMENTAL
Intervention: Gentle breast stimulation for 1.5 hours in hospital and then for three hours daily for three days at home.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gentle breast stimulation for the same period of time and under the same conditions (after crossover).
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no breast stimulation).
Number of subjects: 100

Group type: COMPARATOR
Intervention: Extreatment group (previously stimulated group during crossover).
Number of subjects: 100
Study: 31996978

Group type: COMPARATOR
Intervention: FV+ (standard food parcel plus the recommended daily amount of fruit and vegetables)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Snacks-+FV+ (standard food parcel with replacement of unhealthy snacks by staple foods plus the recommended daily amount of fruit and vegetables)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Snacks- (standard food parcel with replacement of unhealthy snacks by staple foods)
Number of subjects: 163
Study: 29731121

Group type: EXPERIMENTAL
Intervention: Hospitalization for HFrEF
Number of subjects: 4024
Study: 27833172

Group type: EXPERIMENTAL
Intervention: Cranberry supplementation (1500 mg cranberry fruit powder for a mean of 30 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (similar amount as cranberry group)
Number of subjects: 64
Study: 25460722

Group type: EXPERIMENTAL
Intervention: Explosive-type resistance training (EMRT) for 12 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Explosive-type resistance training (EMRT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not exercising)
Number of subjects: 16
Study: 23328238

Group type: EXPERIMENTAL
Intervention: MC + PEEK cage
Number of subjects: 51

Group type: COMPARATOR
Intervention: Anterior cervical plate with PEEK cage or titanium mesh
Number of subjects: 51
Study: 20123819

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 179
Study: 19289436

Group type: EXPERIMENTAL
Intervention: Half-time (HT) gated myocardial SPECT images processed with OSEM-RR plus AC
Number of subjects: 212

Group type: COMPARATOR
Intervention: Full-time (FT) gated myocardial SPECT images processed with FBP and OSEM
Number of subjects: 212

Group type: COMPARATOR
Intervention: Test-retest repeatability using FT images (FBP reconstruction)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: HT images processed with the new algorithm
Number of subjects: 212
Study: 15838756

Group type: EXPERIMENTAL
Intervention: (3)He‐MRI
Number of subjects: 14

Group type: COMPARATOR
Intervention: HRCT
Number of subjects: 14
Study: 12913704

Group type: EXPERIMENTAL
Intervention: 0.2 M KCl
Number of subjects: 78

Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 78
Study: 10485720

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg orally at onset of labour and 2 mg/kg to babies within 72 h of birth
Number of subjects: 626

Group type: COMPARATOR
Intervention: Zidovudine 600 mg orally to the mother at onset of labour and 300 mg every 3 h until delivery, and 4 mg/kg orally twice daily to babies for 7 days after birth
Number of subjects: 626
Study: 8941752

Group type: COMPARATOR
Intervention: Pulpectomy alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pulpectomy with trephination
Number of subjects: 17
Study: 2007938

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 419
Study: 6128282

Group type: EXPERIMENTAL
Intervention: Combination of pseudoephedrine and triprolidine administered every 6 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triprolidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pseudoephedrine
Number of subjects: 0
Study: 31981056

Group type: EXPERIMENTAL
Intervention: FNS (fans and showers)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CTL (shade only)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: FN (fans only)
Number of subjects: 36
Study: 29453374

Group type: EXPERIMENTAL
Intervention: ARB group
Number of subjects: 2

Group type: COMPARATOR
Intervention: non-ARB group
Number of subjects: 2
Study: 26742062

Group type: EXPERIMENTAL
Intervention: Intraduodenal hydrolysed whey protein at 2.1 kJ/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraduodenal hydrolysed whey protein at 6.3 kJ/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraduodenal hydrolysed whey protein at 12.5 kJ/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 16
Study: 24290597

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg of elemental Ca/d as CaCO3)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22771100

Group type: EXPERIMENTAL
Intervention: 3F pancreatic duct stent (PS) placement
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non-stent (NS) group
Number of subjects: 101
Study: 20038323

Group type: EXPERIMENTAL
Intervention: Narcotrend monitoring
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard clinical practice monitoring
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 18663165

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride, 3.75 g/d
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 16459895

Group type: EXPERIMENTAL
Intervention: Words with schwa deleted
Number of subjects: 0

Group type: COMPARATOR
Intervention: Words retaining schwa
Number of subjects: 0
Study: 14649577

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study: 11107459

Group type: EXPERIMENTAL
Intervention: Diet and activity intervention during pregnancy (individual diet counselling, physical activity sessions)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Diet and activity intervention during pregnancy
Number of subjects: 219
Study: 8841863

Group type: EXPERIMENTAL
Intervention: Continuous thoracic paravertebral infusion of bupivacaine (loading dose of 15 mL of 0.375% bupivacaine, plus an infusion of 5 mL of 0.25% bupivacaine every hour)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bolus regimen of 20 mL of 0.375% bupivacaine every 6 hours
Number of subjects: 30
Study: 1536215

Group type: EXPERIMENTAL
Intervention: 0.5 mg micronized 17 beta-estradiol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1.0 mg micronized 17 beta-estradiol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 2.0 mg micronized 17 beta-estradiol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1.0 mg micronized 17 beta-estradiol (after double-blind phase)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Micronized 17 beta-estradiol (previously used)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 51
Study: 6369979

Group type: EXPERIMENTAL
Intervention: Prophylactic oral nonabsorbable antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 31008751

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dexmedetomidine 0 µg/kg (control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 64
Study: 28820320

Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Fibrin (PRF) with open flap debridement (OFD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (OFD alone)
Number of subjects: 17
Study: 26363333

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 162

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 162
Study: 24616335

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg) or Amlodipine (5 mg)
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Double therapy (Aliskiren + Hydrochlorothiazide or Amlodipine)
Number of subjects: 1759

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1759
Study: 22081150

Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3.75 mg bevacizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no bevacizumab)
Number of subjects: 80
Study: 19639211

Group type: EXPERIMENTAL
Intervention: 3 cycles of carboplatin and docetaxel (A1)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 2 cycles of carboplatin and docetaxel (A2)
Number of subjects: 83
Study: 17203360

Group type: EXPERIMENTAL
Intervention: Self-reported community-acquired complicated course of UTIs
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Age above 60 years
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Chronic use of antibiotics
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: More than 6 physician contacts in previous year
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Hospitalization in previous year
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Renal disease
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Incontinence of urine
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 1151
Study: 15640536

Group type: EXPERIMENTAL
Intervention: Routine functional testing (FT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Selective functional testing (FT)
Number of subjects: 61
Study: 10715251

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH)
Number of subjects: 208
Study: 9370765

Group type: EXPERIMENTAL
Intervention: Audiovisual (video) resources
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oral resources
Number of subjects: 104
Study: 1397671

Group type: EXPERIMENTAL
Intervention: Pimobendan (UDCG 115)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study: 2409371

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 26
Study: 30638396

Group type: EXPERIMENTAL
Intervention: Bacillus clausii UBBC-07
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29293018

Group type: EXPERIMENTAL
Intervention: Partner's scent
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Stranger's scent
Number of subjects: 96

Group type: COMPARATOR
Intervention: Neutral scent
Number of subjects: 96
Study: 27566848

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 22795164

Group type: EXPERIMENTAL
Intervention: 10mg/kg dexamethasone intravenously at the beginning of the operation (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 doses of 10mg/kg dexamethasone intravenously at the beginning of the operation and 24 hours after (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 doses of 10mg/kg dexamethasone intravenously at the beginning of the operation, before osteotomy, and 24 hours after (Group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No dexamethasone or controlled hypotension (Group IV - Control)
Number of subjects: 60
Study: 20307224

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-generation 5-HT3RAs
Number of subjects: 0
Study: 18206133

Group type: EXPERIMENTAL
Intervention: Myofeedback training in combination with ergonomic counselling (Mfb/EC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ergonomic counselling alone (EC)
Number of subjects: 36
Study: 16897249

Group type: EXPERIMENTAL
Intervention: Neurotropin (3 ml) combined with saline (3 ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1% Mepivacaine (6 ml)
Number of subjects: 15
Study: 12916011

Group type: EXPERIMENTAL
Intervention: d4T+3TC
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: d4T+ddI
Number of subjects: 126

Group type: COMPARATOR
Intervention: AZT+3TC
Number of subjects: 126
Study: 10954955

Group type: EXPERIMENTAL
Intervention: Cefdinir (300 mg twice daily for 5 days)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Loracarbef (400 mg twice daily for 7 days)
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 586

Group type: COMPARATOR
Intervention: Loracarbef
Number of subjects: 586
Study: 8769695

Group type: EXPERIMENTAL
Intervention: Combination of hydroxyurea and interferon alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxyurea monotherapy
Number of subjects: 0
Study: 1376577

Group type: EXPERIMENTAL
Intervention: Ampicillin/Metronidazole combination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carbenicillin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis
Number of subjects: 100